HLN

HILTON HOTELS CORP 8% QUARTERLY INTEREST BDS 8/15/01

HLN

Market cap $199M

Overview Fund Activity

Delisted

HLN was delisted on the 23rd of October, 2007.

Back to rankings

Consumer Discretionary Lodging

Financial journalist opinion

School's in and immune systems are up, with new Emergen-C Junior Crystals for kids

Help keep your kids smiling and sniffle-free this back-to-school season with a tasty new “popping” boost of immune-supporting vitamins and minerals. Help keep your kids smiling and sniffle-free this back-to-school season with a tasty new “popping” boost of immune-supporting vitamins and minerals.

School's in and immune systems are up, with new Emergen-C Junior Crystals for kids

Haleon Plc (HLN) Presents At Barclays 18th Annual Global Consumer Staples Conference 2025 Transcript

Haleon plc (NYSE:HLN ) Barclays 18th Annual Global Consumer Staples Conference 2025 September 2, 2025 11:15 AM EDT Company Participants Brian McNamara - CEO & Executive Director Conference Call Participants Warren Ackerman - Barclays Bank PLC, Research Division Presentation Warren Ackerman Head of European Consumer Equity Research Let's kickoff with the second session today. So welcome, everybody.

Haleon Plc (HLN) Presents At Barclays 18th Annual Global Consumer Staples Conference 2025 Transcript

Proactive Investors

Haleon's resilience and brand power shine through in Q2

Barclays has repeated its 'overweight' call and 430p price target for Haleon PLC (LSE:HLN, NYSE:HLN) following a solid set of second-quarter results. In a note issued on Friday, it noted that the consumer health group continues to deliver organic revenue growth ahead of expectations.

Haleon plc (HLN) Q2 2025 Q&A Earnings Call Transcript

Haleon plc (NYSE:HLN ) Q2 2025 Earnings Q&A Conference July 31, 2025 4:30 AM ET Company Participants Brian James McNamara - CEO & Executive Director Dawn Amanda Allen - CFO & Director Jo Russell - Head, IR Conference Call Participants Callum Elliott - Sanford C. Bernstein & Co., LLC.

Haleon plc (HLN) Q2 2025 Q&A Earnings Call Transcript

CNBC Television

Haleon CEO: 'Quite optimistic about emerging market growth'

Brian McNamara, chief executive of of Haleon said the company is "quite optimistic about emerging market growth," whilst still developing a "great" business in developed markets.

Haleon CEO: 'Quite optimistic about emerging market growth'

UK's Haleon cuts annual organic revenue growth forecast

British consumer healthcare company Haleon lowered its annual organic revenue growth forecast to 3.5% on Thursday, citing weaker performance in the United States.

UK's Haleon cuts annual organic revenue growth forecast

Zacks Investment Research

HLN vs. SYK: Which Stock Is the Better Value Option?

Investors interested in Medical - Products stocks are likely familiar with Haleon PLC Sponsored ADR (HLN) and Stryker (SYK). But which of these two stocks offers value investors a better bang for their buck right now?

HLN vs. SYK: Which Stock Is the Better Value Option?

Zacks Investment Research

Down 7.4% in 4 Weeks, Here's Why Haleon PLC Sponsored ADR (HLN) Looks Ripe for a Turnaround

Haleon PLC Sponsored ADR (HLN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down 7.4% in 4 Weeks, Here's Why Haleon PLC Sponsored ADR (HLN) Looks Ripe for a Turnaround

Haleon Breaks Ground on new £130m Global Oral Health Innovation Centre

LONDON--(BUSINESS WIRE)-- #Groundbreaking--This week, Haleon, a global leader in consumer health and maker of leading brands such as Sensodyne, parodontax and Polident, broke ground on its new Global Oral Health Innovation Centre in Weybridge, Surrey. This state-of-the-art facility will enhance Haleon's science capabilities, accelerate innovation, and serve as a centre of excellence for global oral health research. The groundbreaking ceremony, attended by UK Minister Baroness Jones, marks an important step in Ha.

Haleon Breaks Ground on new £130m Global Oral Health Innovation Centre

HALEON APPOINTS CARL HANEY AS CHIEF R&D OFFICER

LONDON , June 24, 2025 /PRNewswire/ -- Haleon (LSE: HLN) (NYSE: HLN) today announces the appointment of Carl Haney as Chief Research & Development Officer. Carl will join Haleon on 1 August 2025.

HALEON APPOINTS CARL HANEY AS CHIEF R&D OFFICER

See News Rankings

Charts implemented using Lightweight Charts™